CL posts better-than-expected first-quarter 2025 results. Results benefited from organic sales growth, robust volume and pricing performance.
Although the revenue and EPS for Colgate-Palmolive (CL) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Colgate-Palmolive (CL 0.36%), a leading manufacturer of consumer products in Oral Care, Personal Care, Home Care, and Pet Nutrition, posted its Q1 2025 earnings on April 25, 2025. However, its GAAP revenue of $4.9 billion decreased 3.1% from Q1 2024, despite exceeding estimates by $45 million.
Colgate-Palmolive Co (NYSE:CL) has cut its full-year earnings outlook, citing the impact of tariffs and currency headwinds, even as it posted first-quarter earnings that topped Wall Street expectations thanks to improved margins. The consumer goods maker now expects full-year organic sales growth of 2% to 4%, down from a prior forecast of 3% to 5%.
Colgate-Palmolive (CL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.86 per share a year ago.
Colgate-Palmolive (CL) on Friday reported better-than-expected first-quarter results and lifted its full-year sales outlook, although it lowered its profit projection.
Colgate-Palmolive posted a higher profit in the first quarter but lowered 2025 earnings guidance due to tariffs.
CL's first-quarter results are likely to show sales pressure from macro headwinds, partially offset by margin gains from pricing and productivity.
Beyond analysts' top -and-bottom-line estimates for Colgate-Palmolive (CL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Colgate-Palmolive achieved over $20 billion in revenue in 2024, driven by strong brand identity, operational discipline, and a diversified product portfolio across Oral Care, Personal Care, Home Care, and Pet Nutrition. The company maintained profitability despite inflation, with a 14.4% margin, and continued to invest in marketing and R&D, enhancing brand differentiation and price stability. Financially robust, Colgate-Palmolive showed significant revenue and margin growth, generating record free cash flow, and is well-positioned for 2025 with a "Buy" rating and a target share price of $100.08.
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CL benefits from robust pricing and productivity initiatives. The company's innovation strategy also bodes well.